Functional assessments in repeat-dose toxicity studies: The art of the possible

Toxicology Research

Volumn 2, Issue 4, 2013, Pages 209-234

  Redfern, Will S ^a   Ewart, Lorna C ^a   Lainée, Pierre ^a,b   Pinches, Mark ^a   Robinson, Sally ^a   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CARCINOGEN;

ANESTHESIA; ARTERIAL PRESSURE; BLOOD PRESSURE; BODY TEMPERATURE; CARDIOVASCULAR SYSTEM; COMPUTER MODEL; DIET RESTRICTION; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EQUIPMENT; FUNCTIONAL ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMPLANTATION; KIDNEY; LABORATORY; LIVER; LIVER FUNCTION; MEASUREMENT; METHODOLOGY; MORPHOLOGY; NERVOUS SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOLOGY; PRIORITY JOURNAL; REPEAT DOSE TOXICITY; RESPIRATORY SYSTEM; REVIEW; RISK ASSESSMENT; SCREENING; SINGLE DRUG DOSE; TARGET ORGAN; TELEMETRY; TOXICITY; TOXICOKINETICS;

EID: 84879350161     PISSN: 2045452X     EISSN: 20454538     Source Type: Journal    
DOI: 10.1039/c3tx20093k     Document Type: Review

References (253)

1. T. Kennedy Managing the drug discovery/development interface Drug Discovery Dev. 1997 2 436 444
2. K. E. Lasser P. D. Allen S. J. Woolhandler D. U. Himmelstein S. M. Wolfe D. H. Bor Timing of new black box warnings and withdrawals for prescription medications JAMA, J. Am. Med. Assoc. 2002 287 2215 2220
3. I. Kola J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004 3 711 715
4. J. Arrowsmith Trial watch. Phase II failures: 2008-2010 Nat. Rev. Drug Discovery 2011 10 328 329
5. J. Arrowsmith Trial watch. Phase III and submission failures: 2007-2010 Nat. Rev. Drug Discovery 2011 10 87
6. M. Fung A. Thornton K. Mybeck J. Hsiao-hui Wu K. Hornbuckle E. Muniz Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999 Drug Inf. J. 2001 35 293 317
7. J. L. Stevens T. K. Baker The future of drug safety testing: expanding the view and narrowing the focus Drug Discovery Today 2009 14 162 167
8. J. S. MacDonald R. T. Robertson Toxicity testing in the 21st century: a view from the pharmaceutical industry Toxicol. Sci. 2009 110 40 46
9. J. P. Valentin, M. Keisu and T. G. Hammond, Predicting human adverse drug reactions from non-clinical safety studies, in Clinical Trials Handbook, ed., S. C. Gad, John Wiley & Sons, Inc., New Jersey, USA, 2009, ch. 4, pp. 87-113
10. W. S. Redfern L. Ewart T. G. Hammond R. Bialecki L. Kinter S. Lindgren C. E. Pollard R. Roberts M. G. Rolf J.-P. Valentin Impact and frequency of different toxicities throughout the pharmaceutical life cycle Toxicologist 2010 114 S1 1081
11. W. S. Redfern, J.-P. Valentin and T. G. Hammond, Impact and frequency of different toxicities during clinical development and therapeutic use during 2010. Proc. Society of Toxicology, 50th Anniversary Meeting, Washington D.C., USA, 2011
12. H. Laverty C. Benson E. Cartwright M. Cross C. Garland T. Hammond C. Holloway N. McMahon J. Milligan B. Park M. Pirmohamed C. Pollard J. Radford N. Roome P. Sager S. Singh T. Suter W. Suter A. Trafford P. Volders R. Wallis R. Weaver M. York J. Valentin How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 2011 163 675 693
13. M. Sibille Y. Donazzolo F. Lcoz E. Krupka After the London tragedy, is it possible to consider Phase I is safe? Br. J. Clin. Pharmacol. 2006 62 502 503
14. H. Olson G. Betton D. Robinson K. Thomas A. Monro G. Kolaja P. Lilly J. Sanders G. Sipes W. Bracken M. Dorato K. Van Deun P. Smith B. Berger A. Heller Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 2000 32 56 67
15. W. S. Redfern L. Carlsson A. S. Davis W. G. Lynch I. MacKenzie S. Palethorpe P. K. S. Siegl I. Strang A. T. Sullivan R. Wallis A. J. Camm T. G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 2003 58 32 45
16. T.-J. Aw S. J. Haas D. Liew H. Krum Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure Arch. Intern. Med. 2005 165 490 496
17. S. H. Kim Y. M. Lee S. H. Jee C. M. Nam Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials Obesity Res. 2003 11 1116 1123
18. P. T. Maddox J. Saunders S. S. Chandrasekhar Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology Laryngoscope 2009 119 1586 1589
19. R. Ratner M. Nauck C. Kapitza V. Asnaghi M. Boldrin R. Balena Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study Diabetic Med. 2010 27 556 562
20. D. Brott H. Jones S. Gould J. P. Valentin G. Evans R. J. Richardson C. Louden Current status and future directions for diagnostic markers of drug-induced vascular injury Cancer Biomark. 2005 1 15 28
21. S. G. E. Hart Assessment of renal injury in vivo J. Pharmacol. Toxicol. Methods 2005 52 30 45
22. P. Y. Muller F. Dieterle Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring Expert Opin. Drug Metab. Toxicol. 2009 5 1023 1038
23. K. J. Boudonck D. J. Rose E. D. Karoly D. P. Lee K. A. Lawton P. J. Lapinskas Metabolomics for early detection of drug-induced kidney injury: review of the current status Bioanalysis 2009 1 1645 1663
24. J. P. Piccini D. J. Whellan B. R. Berridge J. K. Finkle S. D. Pettit N. Stockbridge J.-P. Valentin H. M. Vargas M. W. Krucoff Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative Am. Heart J. 2009 158 317 326
25. J. M. Tarrant Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use Toxicol. Sci. 2010 117 4 16
26. R. K. Chetty J. S. Ozer A. Lanevschi I. Schuppe-Koistinen D. McHale J. S. Pears J. Vonderscher F. D. Sistare F. Dieterle A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association Clin. Pharmacol. Ther. 2010 88 260 262
27. A. K. Goetz B. P. Singh M. Battalora J. M. Breier J. P. Bailey A. C. Chukwudebe E. R. Janus Current and future use of genomics data in toxicology: opportunities and challenges for regulatory applications Regul. Toxicol. Pharmacol. 2011 61 141 153
28. W. M. S. Russel and R. L. Burch, The Principles of Humane Experimental Technique, Methuen, London, 1959. Reprinted by Universities Federation for Animal Welfare, Potters Bar, UK, 1992
29. K. A. Keller and C. Banks, Multidose general toxicology studies, in Toxicological Testing Handbook: Principles, Applications and Data Interpretation, ed., K. A. Keller, and, D. Jacobson-Kram, Taylor & Francis Ltd., 2nd edn, 2006, pp. 149-184
30. P. Baldrick Safety evaluation to support first-in-man investigations II: toxicology studies Regul. Toxicol. Pharmacol. 2008 51 237 243
31. Anon. ICH M3(R2): Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, 2009. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Multidisciplinary/M3-R2/Step4/M3-R2-Guideline.pdf
32. S. S. Sparrow S. Robinson S. Bolam C. Bruce A. Danks D. Everett S. Fulcher R. E. Hill H. Palmer E. W. Scott K. L. Chapman Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review Regul. Toxicol. Pharmacol. 2011 61 222 229
33. J. A. Herlich P. Taggart J. Proctor P. Stahle R. Colis L. Hall M. Pugsley The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program Proc. West. Pharmacol. Soc. 2009 52 94 98
34. K. W. Hew, Juvenile animal toxicology studies, in Toxicological Testing Handbook: Principles, Applications and Data Interpretation, ed., K. A. Keller, and, D. Jacobson-Kram, Taylor & Francis Ltd, 2nd edn, 2006, pp. 265-304
35. Anon. ICH S5(R2): Detection of toxicity to reproduction for medicinal products and toxicity to male fertility, 2005. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Safety/S5-R2/Step4/S5-R2-Guideline.pdf
36. Anon. FDA Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products, 2006. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf
37. Anon. Committee for Human Medicinal Products (CHMP). Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications. EMEA/CHMP/SWP/169215/2005, 2008. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003305.pdf
38. Anon. OECD: Guidance document on mammalian reproductive toxicity testing and assessment. ENV/JM/MONO(2008)16, 2008. http://www.oecd.org/ officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2008)16&doclanguage= en
39. P. Baldrick Juvenile animal testing in drug development-is it useful? Regul. Toxicol. Pharmacol. 2010 57 291 299
40. M. A. Dorato J. A. Engelhart The no-observed-adverse-effect-level in drug safety evaluations: use, issues and definition(s) Regul. Toxicol. Pharmacol. 2005 42 265 274
41. W. S. Redfern J.-P. Valentin Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010 J. Pharmacol. Toxicol. Methods 2011 64 102 110
42. S. Alder G. Zbinden Neurobehavioral tests in single- and repeated-dose toxicity studies in small rodents Arch. Toxicol. 1983 54 1 23
43. G. Zbinden, Neglect of function and obsession with structure in toxicity testing, in Proceedings of 9th International Congress of Pharmacology, Macmillan Press, New York, 1984, vol. 1, pp. 43-49
44. G. Zbinden Predictive value of animal studies in toxicology Regul. Toxicol. Pharmacol. 1991 14 167 177
45. T. Matsuzawa M. Hashimoto N. Nara M. Yoshida S. Tamura T. Igarashi Current status of conducting function tests in repeated dose toxicity studies in Japan J. Toxicol. Sci. 1997 22 375 382
46. J. Luft G. Bode Integration of safety pharmacology endpoints into toxicology studies Fund. Clin. Pharmacol. 2002 16 91 103
47. A. J. Harkin J. M. O'Donnell J. P. Kelly A combined and comparative study of physiologic and behavioural parameters in a systemic toxicity test J. Am. Assoc. Lab. Anim. Sci. 2003 42 31 38
48. J. B. Ruffin Functional testing for behavioural toxicity: a dimension in experimental environmental toxicity J. Occup. Med. 1963 5 117 121
49. R. W. Brimblecombe The use of behavioral and neuropharmacological methods in toxicology J. Pharmacol. Methods 1979 2 91 96
50. V. C. Moser Screening approaches to neurotoxicity: a functional observational battery J. Am. Coll. Toxicol. 1989 8 85 93
51. G. C. Haggerty Development of Tier I neurobehavioral testing capabilities for incorporation into pivotal rodent safety assessment studies J. Am. Coll. Toxicol. 1989 8 53 69
52. V. C. Moser G. C. Becking R. C. MacPhail B. M. Kulig The IPCS collaborative study on neurobehavioral screening methods Fund. Appl. Toxicol. 1997 35 143 151
53. I. Kodama K. Kamiya J. Toyama Cellular electropharmacology of amiodarone Cardiovasc. Res. 1997 35 13 29
54. K. P. Maung S. Storey J. McKay A. Bigley D. Heathcote K. Elliott J.-P. Valentin T. G. Hammond W. S. Redfern Validation of an OptoMotry system for measurement of visual acuity in Han Wistar rats J. Pharmacol. Toxicol. Methods 2008 58 152
55. S. G. Nodop Mazurek J. Li G. H. Nabozny G. A. Reinhart A. C. Muthukumarana P. C. Harrison R. M. Fryer Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors J. Pharmacol. Toxicol. Methods 2011 64 89 96
56. P. Dogterom G. Zbinden G. K. Reznik Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview Crit. Rev. Toxicol. 1992 22 203 241
57. P. Greaves Patterns of drug-induced cardiovascular pathology in the beagle dog: relevance for humans Exp. Toxicol. Pathol. 1998 50 283 293
58. D. L. Misner C. Frantz L. Guo M. R. Gralinski P. B. Senese J. Ly M. Albassam K. L. Kolaja Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys Br. J. Pharmacol. 2012 165 2771 2786
59. Anon. ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, 1997. http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Safety/S6-R1/Step4/S6-Guideline.pdf
60. Anon. ICH S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. CPMP/ICH/302/95 (Revised version (R1) finalised June 2011), 2011
61. Anon. FDA Guidance for Industry, Investigators and Reviewers: Exploratory IND Studies, 2006. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf?utm-campaign= Google2&utm-source=fdaSearch&utm-medium=website&utm-term= exploratoryIND&utm-content=1
62. Anon. Nonclinical evaluation for anticancer pharmaceuticals, 2009. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S9/ Step4/S9-Step4-Guideline.pdf
63. H. Cheng T. Force Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics Circ. Res. 2010 106 21 34
64. C. Zuppinger T. M. Suter Cancer therapy-associated cardiotoxicity and signaling in the myocardium J. Cardiovasc. Pharmacol. 2010 56 141 146
65. H. R. Mellor A. R. Bell J. P. Valentin R. R. Roberts Cardiotoxicity associated with targeting kinase pathways in cancer Toxicol. Sci. 2011 120 14 32
66. P. J. Barter M. Caulfield M. Eriksson S. M. Grundy J. J. Kastelein M. Komajda J. Lopez-Sendon L. Mosca J. C. Tardif D. D. Waters C. L. Shear J. H. Revkin K. A. Buhr M. R. Fisher A. R. Tall B. Brewer for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 2007 357 2109 2122
67. S. Kaul G. A. Diamond Diabetes: Breaking news! Rosiglitazone and cardiovascular risk Nat. Rev. Cardiol. 2010 7 670 672
68. A. J. Scheen Cardiovascular risk-benefit profile of sibutramine Am. J. Cardiovasc. Drugs 2010 10 321 334
69. J. M. Scheiman C. E. Hindley Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events Clin. Ther. 2010 32 667 677
70. P. J. Santosh S. Sattar M. Canagaratnam Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults CNS Drugs 2011 25 737 763
71. S. Mehta H. Chen M. Johnson R. R. Aparasu Risk of serious cardiac events in older adults using antipsychotic agents Am. J. Geriatr. Pharmacother. 2011 9 120 132
72. W. S. Redfern I. D. Wakefield H. Prior C. E. Pollard T. G. Hammond J.-P. Valentin Safety pharmacology-a progressive approach Fund. Clin. Pharmacol. 2002 16 161 173
73. W. Haefely Biological basis of drug-induced tolerance, rebound and dependence. Contribution of recent research on benzodiazepines Pharmacopsychiatry 1986 19 353 361
74. T. G. Hammond L. Carlsson A. S. Davis W. G. Lynch I. MacKenzie W. S. Redfern A. T. Sullivan A. J. Camm Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey Cardiovasc. Res. 2001 49 741 750
75. M. L. Tattersall M. Dymond T. Hammond J. P. Valentin Correction of QT values to allow for changes in heart rate in conscious beagle dogs in toxicology assessment J. Pharmacol. Toxicol. Methods 2006 53 11 19
76. B. D. Guth A. S. Bass R. Briscoe S. Chivers M. Markert P. K. S. Siegl J.-P. Valentin Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies J. Pharmacol. Toxicol. Methods 2009 60 107 116
77. Anon. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes Off. J. Eur. Union 2010 L276 34 79
78. Anon. Committee for Proprietary Medicinal Products (CPMP) Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96, 1997. http://www.ganimed. biz/bibliothek/media/EMEa-CPMP-Dec1997.pdf
79. D. K. Detweiler, The use of electrocardiography in toxicological studies with beagle dogs, in Cardiac Toxicology, ed., T. Balasz, CRC Press, Boca Raton, Florida, 1982, pp. 33-82
80. D. K. Detweiler, Electrocardiography in toxicological studies, in Comprehensive Toxicology, ed., I. G. Snipes, C. A. McQueen, and, A. J. Gandolfi, Pergamon Press, New York, USA, 1997
81. G. E. Macallum B. J. Houston Characterization of cardiac alterations in nonsedated cynomolgus monkeys Am. J. Vet. Res. 2009 54 327 332
82. T. Ohmura M. Chachin S. Tarui A. Nagakura T. Igarashi H. Ikeda K. Ikegami H. Kitagawa S. Uchida Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys Eur. J. Pharmacol. 1999 378 169 175
83. A. S. Bass L. A. Hanson T. A. Jackson Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures J. Pharmacol. Toxicol. Methods 2009 60 51 57
84. K. Taylor C. Gleason Effect of body position on limb lead electrocardiographic findings in sedated cynomolgus macaques (Macaca fascicularis) J. Am. Assoc. Lab. Anim. Sci. 2010 49 352 356
85. R. W. Chui A. Fosdick R. Conner J. Jiang B. A. Bruenner H. M. Vargas Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants J. Pharmacol. Toxicol. Methods 2009 60 58 68
86. H. Prior N. McMahon J. Schofield J.-P. Valentin Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs J. Pharmacol. Toxicol. Methods 2009 60 167 173
87. M. V. Soloviev A. Derchak J. J. Setser E. A. Steinbacher J. L. Klemm D. S. Gumpf L. J. Shellhammer K. R. Kearney R. E. Wilson Concurrent cardiovascular and respiratory evaluation in conscious cynomolgus monkeys J. Pharmacol. Toxicol. Methods 2007 56 e30
88. G. Ward P. Milliken B. Patel N. McMahon Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs J. Pharmacol. Toxicol. Methods 2012 66 106 113
89. H. H. Crosby R. L. Hamlin S. M. Strauch Effects of disopyramide on the electrocardiogram and ventricular function in the unanesthetized dog J. Vet. Pharmacol. Ther. 1984 7 167 175
90. G. Hanton M. Gautier P. Bonnet Use of M-mode and Doppler echocardiography to investigate the cardiotoxicity of minoxidil in beagle dogs Arch. Toxicol. 2004 78 40 48
91. G. Hanton M. Gautier P. Bonnet A. Herbet Effect of milrinone on echocardiographic parameters after single dose in Beagle dogs and relationship with drug-induced cardiotoxicity Toxicol. Lett. 2005 155 307 317
92. H. Prior P. Lainée F. El-Amrani E. Martel S. Richard M. Wyckmans J.-P Valentin Correlation between ejection fraction and dP/dt+ in conscious telemetered dogs dosed with atenolol J. Pharmacol. Toxicol. Methods 2009 60 224 225
93. C. M. Cooper M. Skinner B. Antrobus S. Brown P. Lainée J.-P Valentin Echocardiography: a sensitive, clinically translatable biomarker for cardiac contractility J. Pharmacol. Toxicol. Methods 2011 64 e29
94. D. Konrad K. Weber S. Corney T. R. Allen C. Terrier Echocardiography, color-coded Doppler imaging, and abdominal sonography, a non-invasive method for investigation of heart and aortic morphology and function in female gottingen minipigs: method and reference values for M-mode, B-mode, and flow parameters Comp. Med. 2000 50 405 409
95. T. W. Kurtz K. A. Griffin A. K. Bidani R. L. Davisson J. E. Hall Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research Hypertension 2005 45 299 310
96. M. Feng S. Whitesall Y. Zhang M. Beibel L. D'Alecy K. DiPetrillo Validation of volume-pressure recording tail-cuff blood pressure measurements Am. J. Hypertens. 2008 21 1288 1291
97. E. Bailey C. Grant J. Moors J.-L. Wang J.-G. Napoléoni L. Ewart P. Lainée J.-P. Valentin Simultaneous assessment of blood pressure and respiratory function in dogs: validation of a non-invasive telemetry method J. Pharmacol. Toxicol. Methods 2012 66 187
98. J. L. Mattson P. J. Spencer R. R. Albee A performance standard for clinical and functional observational battery examination of rats J. Am. Coll. Toxicol. 1996 15 239 250
99. C. P. LeBel J. A. Foss Use of a rodent neurotoxicity screening battery in the preclinical safety assessment of recombinant-methionyl human brain-derived neurotrophic factor Neurotoxicology 1996 17 851 863
100. S. A. Horner S. Gould J. P. Noakes N. J. Rattray S. L. Allen E. Zotova J. C. Arezzo Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat Mol. Cancer Therap. 2004 3 783 791
101. W. S. Redfern I. Strang S. Storey C. Heys C. Barnard K. Lawton T. G. Hammond J.-P. Valentin Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds J. Pharmacol. Toxicol. Methods 2005 52 77 82
102. S. Roux E. Sable R. D. Porsolt Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function Curr. Protoc. Pharmacol. 2005
103. S. C. Gad S. E. Gad A functional observational battery for use in canine toxicity studies: development and validation Int. J. Toxicol. 2003 22 415 422
104. T. Karl R. Pabst S. von Hörsten Behavioral phenotyping of mice in pharmacological and toxicological research Exp. Toxicol. Pathol. 2003 55 69 83
105. M. Tontodonati A. Fasdelli E. Moscardo A. Giarola R. Dorigatti A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs J. Pharmacol. Toxicol. Methods 2007 56 265 275
106. E. Moscardo N. Fasdelli A. Giarola M. Tontodonati R. Dorigatti An optimised neurobehavioural observation battery integrated with the assessment of cardiovascular function in the beagle dog J. Pharmacol. Toxicol. Methods 2009 60 198 209
107. D. V. Gauvin T. J. Baird A functional observational battery in non-human primates for regulatory-required neurobehavioral assessments J. Pharmacol. Toxicol. Methods 2008 58 88 93
108. J. J. Lynch V. Castagné P. C. Moser S. W. Mittelstadt Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies J. Pharmacol. Toxicol. Methods 2011 64 74 80
109. N. Onishchenko C. Fischer W. N. Wan Ibrahim S. Negri S. Spulber D. Cottica S. Ceccatelli Prenatal exposure to PFOS or PFOA alters motor function in mice in a sex-related manner Neurotox. Res. 2011 19 452 461
110. J. P. Patterson C. G. Markgraf M. Cirino A. Bass Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds J. Pharmacol. Toxicol. Methods 2005 52 159 167
111. P. Chapillon R. Lalonde N. Jones J. Caston Early development of synchronised walking on the rotarod in rats-effects of training and handling Behav. Brain Res 1998 93 77 81
112. R. D. Porsolt M. Lemaire N. Dürkmüller S. Roux New perspectives in CNS safety pharmacology Fund. Clin. Pharmacol. 2002 16 197 207
113. W. S. Redfern and I. D. Wakefield, Safety Pharmacology, in Toxicological Testing Handbook: Principles, Applications and Data Interpretation, ed., K. Keller, and, D. Jacobson-Kram, Taylor & Francis Ltd, 2nd edn, 2006
114. T. A. Holliday H. J. Nelson D. C. Williams N. Willits Unilateral and bilateral brainstem auditory-evoked response abnormalities in 900 Dalmatian dogs J. Vet. Int. Med. 1992 6 166 174
115. K. M. Crofton K. F. Dean M. G. Menache R. Janssen Trimethyltin effects on auditory function and cochlear morphology Toxicol. Appl. Pharmacol. 1990 105 123 132
116. M. Koch The neurobiology of startle Prog. Neurobiol. 1999 59 107 128
117. R. H. Fitch S. W. Threlkeld M. M. McClure A. M. Peiffer Use of a modified prepulse inhibition paradigm to assess complex auditory discrimination in rodents Brain Res. Bull. 2008 76 1 7
118. T. Takeuchi Y. Kiyama K. Nakamura M. Tsujita I. Matsuda H. Mori Y. Munemoto H. Kuriyama R. Natsume K. Sakimura M. Mishina Roles of the glutamate receptor ε2 and δ2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex Eur. J. Neurosci. 2001 14 153 160
119. W. S. Redfern S. Storey K. Tse Q. Hussain K. P. Maung J.-P. Valentin G. Ahmed A. Bigley D. Heathcote J. S. McKay Evaluation of a convenient method of assessing rodent visual function in safety pharmacology studies: effects of sodium iodate on visual acuity and retinal morphology in albino and pigmented rats and mice J. Pharmacol. Toxicol. Methods 2011 63 102 114
120. W. S. Redfern S. Storey C. Barnard C. Heys L. Williams C. Ebbern D. J. Simpson T. G. Hammond J.-P. Valentin A simple method for estimating pupil diameter in conscious rats and dogs during repeat-dose toxicity studies J. Pharmacol. Toxicol. Methods 2007 56 e50
121. H. Bagheri G. Bompart J. P. Girolami J. L. Montastruc P. Montastruc Is yohimbine-induced increase in salivary secretion a kinin-dependent mechanism? Fund. Clin. Pharmacol. 1992 6 17 20
122. N. McMahon N. A. Robinson E. Martel J.-P. Valentin A method for the long term monitoring of cardiovascular and respiratory function in the Wistar rat Toxicology 2004 202 33 127
123. D. J. Murphy J. P. Renninger D. Schramek Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs J. Pharmacol. Toxicol. Methods 2010 62 47 53
124. K. R. Kearney, M. R. Metea and P. R. Atterson, Validation of respiratory inductance plethysmography in ambulatory cynomolgus monkeys, SOT meeting, Washington, USA, 2011
125. L. L. Lanning, Toxicologic pathology assessment, in Toxicological Testing Handbook: Principles, Applications and Data Interpretation, ed., K. A. Keller, and, D. Jacobson-Kram, Taylor & Francis Ltd., 2nd edn, 2006, pp. 109-133
126. L. Marks D. Cobey L. Ewart E. Fantham N. Moore V. Motyer H. Prior J. P. Valentin An evaluation of the non-invasive faecal pellet assessment method as an early development screen for gastrointestinal liability J. Pharmacol. Toxicol. Methods 2012 66 204
127. H. Penton K. Norton The SmartPill™ for gastrointestinal monitoring in dogs J. Pharmacol. Toxicol. Methods 2009 60 213
128. K. Sagawa F. Li R. Liese S. C. Sutton Fed and fasted gastric pH and gastric residence time in conscious beagle dogs J. Pharm. Sci. 2009 98 2494 2500
129. W. J. Guiney C. Beaumont S. R. Thomas Use of the entero-test, a novel approach for the noninvasive capture of biliary metabolites in dogs Drug Metab. Dispos. 2010 38 851 856
130. C. J. Gordon P. J. Spencer J. Hotchkiss D. B. Miller P. M. Hinderliter J. Pauluhn Thermoregulation and its influence on toxicity assessment Toxicology 2008 244 87 97
131. W. J. Kort J. M. Hekking-Weijma M. T. TenKate V. Sorm R. VanStrik A microchip implant system as a method to determine body temperature of terminally ill rats and mice Lab. Anim. 1998 32 260 269
132. H. Prior V. Motyer D. Cobey L. Marks L. Ewart W. S. Redfern J.-P. Valentin Inclusion of microchip transponder body temperature measurements in safety pharmacology and toxicology studies J. Pharmacol. Toxicol. Methods 2012 66 192
133. H. Prior V. Motyer D. Cobey L. Marks L. Ewart J.-P. Valentin Non-invasive methods of body temperature measurement in rats J. Pharmacol. Toxicol. Methods 2012 66 192
134. H. Ishida T. Mitamura Y. Takahashi A. Hisatomi Y. Fukuhara K. Murato K. Ohara Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats Toxicology 1997 123 167 175
135. O. P. McGuinness J. E. Ayala M. R. Laughlin D. H. Wasserman NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse Am. J. Physiol. Endocrinol. Metab. 2009 297 E849 E855
136. M. Tsunoda N. Kobayashi T. Ide M. Utsumi M. Nagasawa K. Murakami A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet Am. J. Physiol. Endocrinol. Metab. 2008 294 E2833 E2840
137. J. D. Wagner L. Zhang K. Kavanagh G. M. Ward J. E. Chin J. R. Hadcock B. J. Auerbach H. J. Harwood A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys J. Pharmacol. Exp. Ther. 2010 335 103 113
138. B. Christoffersen U. Ribel K. Raun V. Golozoubova G. Pacini Evaluation of different methods for assessment of insulin sensitivity in Göttingen minipigs: introduction of a new, simpler method Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009 297 R1195 R1201
139. H. Zong C.-C. Wang B. Vaitheesvaren I. J. Kurland W. Hong J. E. Pessin Enhanced energy expenditure, glucose utilization, and insulin sensitivity in VAMP8 null mice Diabetes 2011 60 30 38
140. K. Keiver S. Duggal M. E. Simpson Ethanol administration results in a prolonged decrease in blood ionized calcium levels in the rat Alcohol 2005 37 173 178
141. S. W. Borron M. Stonerook F. Reid Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs Clin. Toxicol. 2006 44 Suppl 1 5 15
142. E. Zini S. Moretti F. Tschuor C. E. Reusch Evaluation of a new portable glucose meter designed for the use in cats Schw. Arch. Tierheil. 2009 151 448 451
143. M. Eddleston J. M. Street I. Self A. Thompson T. King N. Williams G. Naredo K. Dissanayake L.-M. Yu F. Worek H. John S. Smith H. Thiermann J. B. Harris R. E. Clutton A role for solvents in the toxicity of agricultural organophosphorus pesticides Toxicology 2012 294 94 103
144. P. C. Even A. Mokhtarian A. Pele Practical aspects of indirect calorimetry in laboratory animals Neurosci. Biobehav. Rev. 1994 18 435 447
145. M. Markert A. Klumpp T. Trautmann B. Guth A novel propellant-free inhalation drug delivery system for cardiovascular drug safety evaluation in conscious dogs J. Pharmacol. Toxicol. Methods 2004 50 109 119
146. S. G. Rosolen F. Rigaudiere J. F. Le Gargasson M. G. Brigell Recommendations for a toxicological screening ERG procedure in laboratory animals Doc. Ophthalmol. 2005 110 57 66
147. H. H. Schaumburg E. Zotova C. Raine M. Tar J. Arezzo The rat caudal nerves: a model for experimental neuropathies J. Peripher. Nerv. Syst. 2010 15 128 139
148. S. Authier M. Legaspi D. Gauvin F. Chaurand S. Fournier E. Troncy Validation of respiratory safety pharmacology models: conscious and anaesthetized beagle dogs J. Pharmacol. Toxicol. Methods 2009 57 52 60
149. D. Raeburn S. L. Underwood M. E. Villamil Techniques for drug delivery to the airways, and the assessment of lung function in animal models J. Pharmacol. Toxicol. Methods 1992 27 143 159
150. D. J. Murphy Assessment of respiratory function in safety pharmacology Fund. Clin. Pharmacol. 2002 16 183 196
151. D. Harris M. Graham J. Price F. Munro A. Templeton R. Young K. Paterson L. Anderson S. Gillies S. McKendrick G. Low L. Patmore R. Bodine M. J. Kallman W. P. Hoffman C. Lee R. K. Wolff Respiratory function in rats restrained for extended periods: assessment of the effects of bethanecol J. Pharmacol. Toxicol. Methods 2005 52 83 89
152. H. G. Hoymann Invasive and noninvasive lung function measurements in rodents J. Pharmacol. Toxicol. Methods 2007 55 16 26
153. L. C. Ewart M. Haley S. Bickerton J. Bright K. Elliott A. McCarthy L. Williams S. A. Ricketts T. Holland J.-P. Valentin Pharmacological validation of a telemetric model for the measurement of bronchoconstriction in conscious rats J. Pharmacol. Toxicol. Methods 2010 61 219 229
154. R. A. Gabel R. A. Ranaei S. D. Kivlighn A new method of measuring renal function in conscious rats without the use of radioisotopes J. Pharmacol. Toxicol. Methods 1996 36 189 197
155. V. Laroute H. P. Lefebvre G. Costes P. L. Toutain Measurement of glomerular filtration rate and effective renal plasma flow in the conscious beagle dog by single intravenous bolus of iohexol and p-aminohippuric acid J. Pharmacol. Toxicol. Methods 1999 41 17 25
156. R. Katayama N. Yamaguchi T. Yamashita S. Watanabe H. Satoh N. Yamagishi K. Furuhama Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample J. Pharmacol. Toxicol. Methods 2010 61 59 64
157. P. J. Chiu A. Barnett G. Tetzloff J. Kaminski Gastric antisecretory properties of SCH 32651 Arch. Int. Pharmacodyn. Therap. 1984 270 116 127
158. M. N. Martinez M. G. Papich Factors influencing the gastric residence of
159. L. Sjödin S. Visser A. Al-Saffar Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs J. Pharmacol. Toxicol. Methods 2011 64 42 52
160. H. R. N. Marona M. B. B. Lucchesi Protocol to refine intestinal motility test in mice Lab. Anim. 2004 38 257 260
161. H. Takikawa Y. Wako N. Sano M. Yamanaka Changes in biliary excretory mechanisms in bile duct-ligated rat Dig. Dis. Sci. 1996 41 256 262
162. D. K. Dalvie N. B. Khosla K. A. Navetta K. E. Brighty Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways Drug Metab. Dispos. 1996 24 1231 1240
163. T. Hara H. Arima F. Hirayama K. Uekama Enhanced bioavailability of a new thiazolidine derivative FPFS-410, an antidiabetic and lipid-lowering drug, after oral administration of its hydroxypropyl-β-cyclodextrin complex to bile duct-cannulated rats J. Pharm. Sci. 2006 95 1771 1782
164. C. J. Gordon Response of the thermoregulatory system to toxic insults Front. Biosci. 2010 2 293 311
165. C. E. Pollard N. Abi-Gerges M. H. Bridgland-Taylor A. Easter A. Harmer T. G. Hammond J. P. Valentin An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk Br. J. Pharmacol. 2010 159 12 21
166. J. P. Valentin C. E. Pollard P. Lainée T. Hammond Value of nonclinical repolarization assays in supporting the discovery and development of safer medicines Br. J. Pharmacol. 2010 159 25 33
167. J. Weirich H. Antoni Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs Basic Res. Cardiol. 1998 93 Suppl 1 125 132
168. M. Hassimoto T. Harada Use of a telemetry system to examine recovery of the cardiovascular system after excitement induced by handling stress in a conscious cynomolgus monkey (Macaca fascicularis) J. Med. Primatol. 2003 32 346 352
169. K. Nahas P. Baneux D. Detweiler Electrocardiographic monitoring in the Göttingen minipig Comp. Med. 2002 52 258 264
170. R. L. Hamlin Non-drug-related electrocardiographic features in animal models in safety pharmacology J. Pharmacol. Toxicol. Methods 2005 52 60 76
171. C. Cros M. Skinner J. Moors P. Lainée J.-P. Valentin Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment Toxicol. Appl. Pharmacol. 2012 265 200 208
172. F. Cools S. Janssens A. Vanlommel A. Teisman R. Towart D. J. Gallacher ECG arrhythmias in non-implanted vs. telemetry-implanted dogs: need for screening before and sufficient recovery time after implantation J. Pharmacol. Toxicol. Methods 2011 64 60 67
173. D. J. Leishman T. W. Beck N. Dybdal D. J. Gallacher B. D. Guth M. Holbrook B. Roche R. M. Wallis Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society J. Pharmacol. Toxicol. Methods 2012 65 93 101
174. M. M. Sleeper J. M. Gaughan C. R. Gleason D. E. Burkett Echocardiographic reference ranges for sedated healthy cynomolgus monkeys (Macaca fascicularis) J. Am. Assoc. Lab. Anim. Sci. 2008 47 22 25
175. H. Tsusaki H. Yonamine A. Tamai M. Shimomoto H. Iwao R. Nagata G. Kito Evaluation of cardiac function in primates using real-time three-dimensional echocardiography as applications to safety assessment J. Pharmacol. Toxicol. Methods 2005 52 182 187
176. C. E. Haberman C. W. Kang J. D. Morgan S. A. Brown Evaluation of oscillometric and Doppler ultrasonic methods of indirect blood pressure estimation in conscious dogs Can. J. Vet. Res. 2006 70 211 217
177. A. Z. Mitchell C. McMahon T. W. Beck R. D. Sarazan Sensitivity of two noninvasive blood pressure measurement techniques compared to telemetry in cynomolgus monkeys and beagle dogs J. Pharmacol. Toxicol. Methods 2010 62 54 63
178. O. Meyer R. Jenni A. Greiter-Wilke A. Breidenbach H. H. Holzgrefe Comparison of telemetry and high-definition oscillometry for blood pressure measurements in conscious dogs: effects of torcetrapib J. Am. Assoc. Lab. Anim. Sci. 2010 49 464 471
179. B. Schmelting Non-invasive blood pressure determination in Macaca fascicularis and Callithrix jacchus by high definition oscillometry J. Pharmacol. Toxicol. Methods 2009 60 234 235
180. B. Schmelting M. Niehoff B. Egner S. H. Korte G. F. Weinbauer High Definition Oscillometry: a novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (Macaca fascicularis) J. Med. Primatol. 2009 38 293 301
181. B. Schmelting M. Niehoff G. F. Weinbauer Integration of hemodynamic endpoints into toxicology studies: torcetrapib and high-definition oscillometry (HDO) in cynomolgus monkeys J. Pharmacol. Toxicol. Methods 2010 62 e42
182. B. Schmelting Ambulatory non-invasive blood pressure recording in a freely moving cynomolgus monkey using High Definition Oscillometry (HDO) and Bluetooth technology J. Pharmacol. Toxicol. Methods 2011 64 e49
183. C. McMahon A. Z. Mitchell J. L. Klein A. C. Jenkins R. D. Sarazan Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys J. Pharmacol. Toxicol. Methods 2010 62 127 135
184. G. Morawietz C. Ruehl-Fehlert B. Kittel A. Bube K. Keane S. Halm A. Heuser J. Hellmann Revised guides for organ sampling and trimming in rats and mice-Part 3 Exp. Toxicol. Pathol. 2004 55 433 449
185. E. Moscardo G. McPhie N. Fasdelli R. Dorigatti K. Meecham An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey J. Pharmacol. Toxicol. Methods 2010 62 95 106
186. G. Froget C. Cruz I. Hubert D. Virley M. Lemaire M. Duxon R. Porsolt The development of an Irwin-like test in the non-human primate for CNS safety assessment J. Pharmacol. Toxicol. Methods 2012 66 164
187. C. V. Vorhees K. D. Acuff-Smith D. R. Minck R. E. Butcher A method for measuring locomotor behavior in rodents: contrast-sensitive computer-controlled video tracking activity assessment in rats Neurotoxicol. Teratol. 1992 14 43 49
188. H. M. Himmel Safety pharmacology assessment of central nervous system function in juvenile and adult rats: effects of pharmacological reference compounds J. Pharmacol. Toxicol. Methods 2008 58 129 146
189. S. M. Smits C. W. Noorlander M. J. H. Kas G. M. J. Ramakers M. P. Smidt Alterations in serotonin signalling are involved in the hyperactivity of Pitx3-deficient mice Eur. J. Neurosci. 2008 27 388 395
190. C. H. Vinkers M. E. Breuer K. G. Westphal S. M. Korte R. S. Oosting B. Olivier L. Groenink Olfactory bulbectomy induces rapid and stable changes in basal and stress-induced locomotor activity, heart rate and body temperature responses in the home cage Neuroscience 2009 159 39 46
191. T. C. Krohn H. Farlov A. K. Hansen The effects of housing on food and water consumption in DA rats Scand. J. Lab. Anim. Sci. 2010 37 1 6
192. Anon. MRC National Centre for the 3Rs, CRACK-IT Scheme, 2012. http://www.crackit.org.uk/crack/crackitchallenges/challenge3-rodentbigbrother
193. C. Froger-Colléaux S. Rompion P. Guillaume R. D. Porsolt V. Castagné P. Moser Continuous evaluation of drug withdrawal in the rat using telemetry: effects of morphine and chlordiazepoxide J. Pharmacol. Toxicol. Methods 2011 64 81 88
194. P. S. Yam V. Penpraze D. Young M. S. Todd A. D. Cloney K. A. Houston-Callaghan J. J. Reilly Validity, practical utility and reliability of Actigraph accelerometry for the measurement of habitual physical activity in dogs J. Small Anim. Pract. 2011 52 86 92
195. T. M. Mann K. E. Williams P. C. Pearce E. A. M. Scott A novel method for activity monitoring in small non-human primates Lab. Anim. 2004 39 169 177
196. A. Papailiou E. Sullivan J. L. Cameron Behaviors in rhesus monkeys (Macaca mulatta) associated with activity counts measured by accelerometer Am. J. Primatol. 2008 70 185 190
197. C. Rose R. C. de Heer S. Horte J. E. van der Harst G. F. Weinbauer B. M. Spruijt Quantified tracking and monitoring of diazepam treated socially housed cynomolgus monkeys Regul. Toxicol. Pharmacol. 2012 62 292 301
198. J. L. Stanley R. Lincoln T. A. Brown L. M. McDonald G. R. Dawson D. S. Reynolds The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines J. Psychopharmacol. 2005 19 221 227
199. Anon. ICHS7A: Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00, 2000. London, November 16, 2000. http://www.emea.eu.int/pdfs/ human/ich/053900en.pdf
200. J. P. Jacky Barometric measurement of tidal volume: effects of pattern and nasal temperature J. Appl. Physiol 1980 49 319 325
201. L. Ewart G. Cullen J.-P. Valentin Optimisation of plethysmography conditions for use in repeat dose toxicity studies Toxicol. Sci. 2008 102 473
202. W. S. Redfern L. Marks C. Barnard D. Cobey C. Grant K. Greenwood L. Ewart H. Prior J.-P. Valentin Streamlined functional measurements for early toxicology studies in rodents J. Pharmacol. Toxicol. Methods 2011 64 e20
203. P. Neumann J. Zinserling C. Haase M. Sydow H. Burchardi Evaluation of respiratory inductive plethysmography in controlled ventilation: measurement of tidal volume and PEEP-induced changes of end-expiratory lung volume Chest 1998 113 443 451
204. R. Guignet G. Bergonzelli V. Schlageter M. Turini P. Kucera Magnet tracking: a new tool for in vivo studies of the rat gastrointestinal motility Neurogastroenterol. Motility 2006 18 472 478
205. C. S. Boillat F. P. Gaschen G. L. Hosgood Assessment of the relationship between body weight and gastrointestinal transit times measured by use of a wireless motility capsule system in dogs Am. J. Vet. Res. 2010 71 898 902
206. C. S. Boillat F. P. Gaschen L. Gaschen R. W. Stout G. L. Hosgood Variability associated with repeated measurements of gastrointestinal tract motility in dogs obtained by use of a wireless motility capsule system and scintigraphy Am. J. Vet. Res. 2010 71 903 908
207. A. Tsukamoto K. Ohno T. Tsukagoshi S. Maeda K. Nakashima K. Fukushima Y. Fujino H. Tsujimoto Real-time ultrasonographic evaluation of canine gastric motility in the postprandial state J. Vet. Med. Sci. 2011 73 1133 1138
208. M. Akimoto N. Nagahata A. Furuya K. Fukushima S. Higuchi T. Suwa Gastric pH profiles of beagle dogs and their use as an alternative to human testing Eur. J. Pharm. Biopharm. 2000 49 99 102
209. S. L. Stockham and M. A. Scott, Urinary system, in Fundamentals of Veterinary Clinical Pathology, Blackwell, 2008, pp. 416-487, ISBN 0-8138-0076-5
210. K. Weingand G. Brown R. Hall D. Davies K. Gossett D. Neptun T. Waner T. Matsuzawa P. Salemink W. Froelke J. P. Provost G. Dal Negro J. Batchelor M. Nomura H. Groetsch A. Boink J. Kimball D. Woodman M. York E. Fabianson-Johnson M. Lupart E. Melloni Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing Fundam. Appl. Toxicol. 1996 29 198 201
211. M. Haas A. C. Kluppel F. Moolenaar D. K. Meijer P. E. de Jong D. de Zeeuw Urine collection in the freely moving rat: reliability for measurement of short-term renal effects J. Pharmacol. Toxicol. Methods 1997 38 47 51
212. B. Schöttker C. Herder H. Müller H. Brenner D. Rothenbacher Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes Diabetes Care 2012 35 879 886
213. F. S. Almy M. M. Christopher D. P. King S. A. Brown Evaluation of cystatin C as an endogenous marker of glomerular filtration rate in dogs J. Vet. Int. Med. 2002 16 45 51
214. J. M. Crawford, in Pathogenic Basis of Disease: Liver and Biliary Tract, ed., V. Kumar, A. Abbas, and, N. Fausto, Elsevier Saunders, 1999, pp. 877-938. ISBN 0-7216-0187-1
215. E. D. Lassen, in Veterinary Hematology and Clinical Chemistry: Laboratory evaluation of the Liver, ed., M. A. Thrall, Lippincott Williams and Wilkins, 2004, ISBN 0-683-30415-1
216. S. L. Stockham and M. A. Scott, Liver function, in Fundamentals of Veterinary Clinical Pathology, Blackwell, 2008, pp. 675-706. ISBN 0-8138-0076-5
217. A. M. Evans C. D. DeHaven T. Barrett M. Mitchell E. Milgram Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems Anal. Chem. 2009 81 6656 6667
218. X. Qiao M. Ye C. F. Liu W. Z. Yang W. J. Miao J. Dong D. A. Guo A tandem mass spectrometric study of bile acids: interpretation of fragmentation pathways and differentiation of steroid isomers Steroids 2012 77 204 211
219. K. P. Tan M. Yang S. Ito Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress Mol. Pharmacol. 2007 72 1380 1390
220. R. J. Vonk C. M. Kneepkens R. Havinga F. Kuipers C. M. Bijleveld Enterohepatic circulation in man. A simple method for the determination of duodenal bile acids J. Lipid Res. 1986 27 901 904
221. T. A. Buchanan P. Cane C. C. Eng G. F. Sipos C. Lee Hypothermia is critical for survival during prolonged insulin-induced hypoglycemia in rats Metabolism 1991 40 330 334
222. A. A. Steiner L. G. Branco Hypoxia-induced anapyrexia: implications and putative mediators Annu. Rev. Physiol. 2004 64 263 288
223. S. J. Swoap The pharmacology and molecular mechanisms underlying temperature regulation and torpor Biochem. Pharmacol. 2008 76 817 824
224. D. E. Rusyniak J. E. Sprague Toxin-induced hyperthermic syndromes Med. Clin. N. Am. 2005 89 1277 1296
225. C. J. Gordon Thermal biology of the laboratory rat Physiol. Behav. 1990 47 963 991
226. L. N. Luong P. Carrive Orexin microinjection in the medullary raphe increases heart rate and arterial pressure but does not reduce tail skin blood flow in the awake rat Neuroscience 2012 202 209 217
227. V. M. Rodríguez M. P. Portillo C. Picó M. T. Macarulla A. Palou Olive oil feeding up-regulates uncoupling protein genes in rat brown adipose tissue and skeletal muscle Am. J. Clin. Nutr. 2002 75 213 220
228. I. Cavero 2012 Annual meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines Expert Opin. Drug Discovery 2013
229. Anon, Guidance for industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, U.S. Food and Drug Administration, 2008, http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf
230. Anon Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 2002 360 1903 1913
231. K. Fox J. S. Borer A. J. Camm N. Danchin R. Ferrari J. L. Lopez Sendon P. G. Steg J. C. Tardif L. Tavazzi M. Tendera for the Heart Rate Working Group Resting heart rate in cardiovascular disease J. Am. Col. Cardiol. 50 823 830
232. M. A. Brockmann A. Kemmling C. Groden Current issues and perspectives in small rodent magnetic resonance imaging using clinical MRI scanners Methods 2007 43 79 87
233. S. A. Perrine F. Ghoddoussi M. S. Michaels E. M. Hyde D. M. Kuhn M. P. Galloway MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain Neurotoxicology 2010 31 654 661
234. M. Sadick U. Attenberger B. Kraenzlin H. Kayed S. O. Schoenberg N. Gretz D. Schock-Kusch Two non-invasive GFR-estimation methods in rat models of polycystic kidney disease: 3.0 Tesla dynamic contrast-enhanced MRI and optical imaging Nephrol. Dial. Transplant 2011 26 3101 3108
235. 177Lu-labeled Tyr3-octreotate radionuclide therapy J. Nucl. Med. 2010 51 1962 1968
236. R. E. Pollard P. A. Dayton K. D. Watson X. Hu I. M. Guracar K. W. Ferrara Motion corrected cadence CPS ultrasound for quantifying response to vasoactive drugs in a rat kidney model Urology 2009 74 675 681
237. G. Ghobadi S. van der Veen B. Bartelds R. A. de Boer M. G. Dickinson J. R. de Jong H. Faber M. Niemantsverdriet S. Brandenburg R. M. Berger J. A. Langendijk R. P. Coppes P. van Luijk Physiological interaction of heart and lung in thoracic irradiation Int. J. Radiat. Oncol., Biol., Phys. 2012 84 e639 e646
238. P. Hockings, in Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays, ed., H. G. Vogel, F. J. Hock, J. Maas, and, D. Mayer, 2006, XXXI, pp. 385-393. Springer reference. ISBN 978-3-540-33442-2
239. Y. Ni G. Marchal G. Lukito J. Yu A. Mühler A. L. Baert MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings Radiology 1994 190 753 758
240. H. Togashi H. Shinzawa T. Matsuo Y. Takeda T. Takahashi M. Aoyama K. Oikawa H. Kamada Analysis of hepatic oxidative stress status by electron spin resonance spectroscopy and imaging Free Radical Biol. Med. 2000 28 846 853
241. Z. Zhi W. O. Cepurna E. C. Johnson J. C. Morrison R. K. Wang Impact of intraocular pressure on changes of blood flow in the retina, choroid, and optic nerve head in rats investigated by optical microangiography Biomed. Opt. Express 2012 3 2220 2233
242. H. Haick M. Hakim M. Patrascu C. Levenberg N. Shehada F. Nakhoul Z. Abassi Sniffing chronic renal failure in rat model by an array of random networks of single-walled carbon nanotubes ACS Nano 2009 3 1258 1266
243. W. Muster A. Breidenbach H. Fischer S. Kirchner L. Müller A. Pähler Computational toxicology in drug development Drug Discovery Today 2008 13 303 310
244. J. Parkinson D. Muthas M. Clark S. Boyer J. P. Valentin L. Ewart Application of data mining and visualization techniques for the prediction of drug-induced nausea in man Toxicol. Sci. 2012 126 275 284
245. D. P. Williams R. Shipley M. J. Ellis S. Webb J. Ward I. Gardner S. Creton Novel in vitro and mathematical models for the prediction of chemical toxicity Toxicol. Res. 2012 2 40 59
246. J. Bowes A. J. Brown J. Hamon W. Jarolimek A. Sridhar G. Waldron S. Whitebread Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat. Rev. Drug Discovery 2012 11 909 922
247. C. E. Thomas Y. Will The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery Expert Opin. Drug Discovery 2012 7 109 122
248. A. Easter M. E. Bell J. R. Damewood W. S. Redfern J.-P. Valentin M. J. Winter C. Fonck R. A. Bialecki Approaches to seizure risk assessment in preclinical drug discovery Drug Discovery Today 2009 14 876 884
249. J. A. Kramer J. E. Sgartz D. L. Morris The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates Nat. Rev.: Drug Discovery 2007 6 636 649
250. J. P. Valentin R. Bialecki L. Ewart T. Hammond D. Leishmann S. Lindgren V. Martinez C. Pollard W. Redfern R. Wallis A framework to assess the translation of safety pharmacology data to humans J. Pharmacol. Toxicol. Methods 2009 60 152 158
251. Anon, Challenge and opportunity on the critical path to new medical products, U.S. Food and Drug Administration, 2004, http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html
252. M. E. Andersen D. Krewski The vision of toxicity testing in the 21st century: moving from discussion to action Toxicol. Sci. 2010 117 17 24
253. P. Y. Muller M. N. Milton The determination and interpretation of the therapeutic index in drug development Nat. Rev. Drug Discovery 2012 11 751 761